Experimental therapies and clinical trials in bone sarcoma

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 8, Issue 6, 2010, Pages 715-725

  Chugh, Rashmi ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Bone sarcoma; Chondrosarcoma; Clinical trial; Ewing's sarcoma; Osteosarcoma

Indexed keywords

ANTINEOPLASTIC AGENT; BETA INTERFERON; BEVACIZUMAB; BISPHOSPHONIC ACID DERIVATIVE; BUSULFAN; CARBOPLATIN; CISPLATIN; CIXUTUMUMAB; CYCLOPHOSPHAMIDE; DASATINIB; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FENRETINIDE; GEMCITABINE; IFOSFAMIDE; IMATINIB; MELPHALAN; METHOTREXATE; N (5 CHLORO 1,3 BENZODIOXOL 4 YL) 7 [2 (4 METHYL 1 PIPERAZINYL)ETHOXY] 5 (TETRAHYDRO 2H PYRAN 4 YLOXY) 4 QUINAZOLINAMINE; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; PEGINTERFERON ALPHA2B; R 1507; SCH 717454; SORAFENIB; TEMSIROLIMUS; TOPOTECAN; UNCLASSIFIED DRUG; VINCRISTINE; ZOLEDRONIC ACID; TUMOR MARKER;

ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RELAPSE; CANCER SURGERY; CANCER SURVIVAL; CHONDROSARCOMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG ACTIVITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; EWING SARCOMA; HUMAN; LUNG METASTASIS; NONHUMAN; OSTEOSARCOMA; RANDOMIZED CONTROLLED TRIAL; REVIEW; SARCOMA; SOFT TISSUE SARCOMA; SOLID TUMOR; STEM CELL TRANSPLANTATION; ANIMAL; ARTICLE; BONE TUMOR; DRUG ANTAGONISM; METABOLISM; MULTIMODALITY CANCER THERAPY; PATHOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; CHONDROSARCOMA; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; HUMANS; OSTEOSARCOMA; SARCOMA, EWING'S; TUMOR MARKERS, BIOLOGICAL;

EID: 77954159106     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2010.0052     Document Type: Review

References (97)

1. Dorfman HD, Czerniak B. Bone cancers. Cancer 1995;75:203-210.
2. Gurney JG, Swenen AR, Bulterys M. Malignant Bone Tumors. In: Gloeckler Ries LA, Smith MA, Gurney JG, et al., eds. Cancer Incidence and Survival Among Children and Adolescents: United States SEER program 1975-1995 (NIH Pub #99-4649). Bethesda, MD: National Institutes of Health; 1999:99-110.
3. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-249.
4. Meyers PA, Heller G, Healey J, et al. Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience. J Clin Oncol 1992;10:5-15.
5. Bramwell VH, Burgers MV, Souhami RL, et al. A randomized comparison of two short intensive chemotherapy regimens in children and young adults with osteosarcoma: results in patients with metastases: a study of the European Osteosarcoma Intergroup. Sarcoma 1997;1:155-160.
6. Souhami RL, Craft AW, Van der Eijken JW, et al. Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup. Lancet 1997;350:911-917.
7. Winkler K, Beron G, Kotz R, et al. Neoadjuvant chemotherapy for osteogenic sarcoma: results of a Cooperative German/Austrian study. J Clin Oncol 1984;2:617-624.
8. Antman K, Crowley J, Balcerzak SP, et al. A Southwest Oncology Group and Cancer and Leukemia Group B phase II study of doxorubicin, dacarbazine, ifosfamide, and mesna in adults with advanced osteosarcoma, Ewing's sarcoma, and rhabdomyosarcoma. Cancer 1998;82:1288-1295.
9. Dahlin DC, Coventry MB. Osteogenic sarcoma. A study of six hundred cases. J Bone Joint Surg Am 1967;49:101-110.
10. Link MP. Adjuvant therapy in the treatment of osteosarcoma. Important Adv Oncol 1986:193-207.
11. Gatta G, Capocaccia R, Stiller C, et al. Childhood cancer survival trends in Europe: a EUROCARE Working Group study. J Clin Oncol 2005;23:3742-3751.
12. Foster L, Dall GF, Reid R, et al. Twentieth-century survival from osteosarcoma in childhood. Trends from 1933 to 2004. J Bone Joint Surg Br 2007;89:1234-1238.
13. Mirabello L, Troisi RJ, Savage SA. Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer 2009;115:1531-1543.
14. Bielack SS, Kempf-Bielack B, Branscheid D, et al. Second and subsequent recurrences of osteosarcoma: presentation, treatment, and outcomes of 249 consecutive cooperative osteosarcoma study group patients. J Clin Oncol 2009;27:557-565.
15. Briccoli A, Rocca M, Salone M, et al. High grade osteosarcoma of the extremities metastatic to the lung: long-term results in 323 patients treated combining surgery and chemotherapy, 1985-2005. Surg Oncol 2009;98:415-420.
16. Kempf-Bielack B, Bielack SS, Jurgens H, et al. Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS). J Clin Oncol 2005;23:559-568.
17. Van Winkle P, Angiolillo A, Krailo M, et al. Ifosfamide, carboplatin, and etoposide (ICE) reinduction chemotherapy in a large cohort of children and adolescents with recurrent/refractory sarcoma: the Children's Cancer Group (CCG) experience. Pediatr Blood Cancer 2005;44:338-347.
18. Chou AJ, Merola PR, Wexler LH, et al. Treatment of osteosarcoma at first recurrence after contemporary therapy: the Memorial Sloan-Kettering Cancer Center experience. Cancer 2005;104:2214-2221.
19. Berrak SG, Pearson M, Berberoglu S, et al. High-dose ifosfamide in relapsed pediatric osteosarcoma: therapeutic effects and renal toxicity. Pediatr Blood Cancer 2005;44:215-219.
20. Navid F, Willert JR, McCarville MB, et al. Combination of gemcitabine and docetaxel in the treatment of children and young adults with refractory bone sarcoma. Cancer 2008;113:419-425.
21. Daw NC, Neel MD, Rao BN, et al. Frontline treatment of localized osteosarcoma without methotrexate: results of the St Jude Children's Research Hospital OS99 trial [abstract]. J Clin Oncol 2009;27(Suppl 1):Abstract 10036.
22. Meyers PA, Schwartz CL, Krailo MD, et al. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival - a report from the Children's Oncology Group. J Clin Oncol 2008;26:633-638.
23. Mori K, Ando K, Heymann D. Liposomal muramyl tripeptide phosphatidyl ethanolamine: a safe and effective agent against osteosarcoma pulmonary metastases. Expert Rev Anticancer Ther 2008;8:151-159. (Pubitemid 351385905)
24. Whelan J, Patterson D, Perisoglou M, et al. The role of interferons in the treatment of osteosarcoma. Pediatr Blood Cancer 2010;54:350-354.
25. Gresser I. Antitumour effects of interferons: past, present and future. Br J Haematol 1991;79(Suppl 1):1-5.
26. Sidky YA, Borden EC. Inhibition of angiogenesis by interferons: effects on tumor- and lymphocyte-induced vascular responses. Cancer Res 1987;47:5155-5161. (Pubitemid 17146488)
27. Siegel BV, Cohen S. Tumor immunity. Fed Proc 1978;37:2212-2214.
28. Muller CR, Smeland S, Bauer HC, et al. Interferon-alpha as the only adjuvant treatment in high-grade osteosarcoma: long term results of the Karolinska Hospital series. Acta Oncol 2005;44:475-480. (Pubitemid 41191780)
29. Roelofs AJ, Thompson K, Gordon S, et al. Molecular mechanisms of action of bisphosphonates: current status. Clin Cancer Res 2006;12:6222s-6230s.
30. Kavanagh KL, Guo K, Dunford JE, et al. The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs. Proc Natl Acad Sci U S A 2006;103:7829-7834.
31. Diel IJ, Solomayer EF, Costa SD, et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 1998;339:357-363.
32. Clezardin P, Ebetino FH, Fournier PG. Bisphosphonates and cancer-induced bone disease: beyond their antiresorptive activity. Cancer Res 2005;65:4971-4974.
33. Iguchi T, Miyakawa Y, Saito K, et al. Zoledronate-induced S phase arrest and apoptosis accompanied by DNA damage and activation of the ATM/Chk1/cdc25 pathway in human osteosarcoma cells. Int J Oncol 2007;31:285-291.
34. Sonnemann J, Eckervogt V, Truckenbrod B, et al. The bisphosphonate pamidronate is a potent inhibitor of human osteosarcoma cell growth in vitro. Anticancer Drugs 2001;12:459-465.
35. Murayama T, Kawasoe Y, Yamashita Y, et al. Efficacy of the third-generation bisphosphonate risedronate alone and in combination with anticancer drugs against osteosarcoma cell lines. Anticancer Res 2008;28:2147-2154.
36. Ory B, Blanchard F, Battaglia S, et al. Zoledronic acid activates the DNA S-phase checkpoint and induces osteosarcoma cell death characterized by apoptosis-inducing factor and endonuclease-G translocation independently of p53 and retinoblastoma status. Mol Pharmacol 2007;71:333-343.
37. Meyers PA, Healey JH, Athanasian E, et al. Addition of pamidronate to chemotherapy for treatment of osteosarcoma is feasible. Presented at Connective Tissue Oncology Society 14th Annual Meeting; November 13-15, 2008; London, United Kingdom.
38. Martin GS. The hunting of the Src. Nat Rev Mol Cell Biol 2001;2:467-475.
39. Yeatman TJ. A renaissance for SRC. Nat Rev Cancer 2004;4:470-480.
40. Webb DJ, Donais K, Whitmore LA, et al. FAK-Src signalling through paxillin, ERK and MLCK regulates adhesion disassembly. Nat Cell Biol 2004;6:154-161.
41. Cantiani L, Manara MC, Zucchini C, et al. Caveolin-1 reduces osteosarcoma metastases by inhibiting c-Src activity and met signaling. Cancer Res 2007;67:7675-7685.
42. Scotlandi K, Zuntini M, Manara MC, et al. CD99 isoforms dictate opposite functions in tumour malignancy and metastases by activating or repressing c-Src kinase activity. Oncogene 2007;26:6604-6618.
43. Manara MC, Bernard G, Lollini PL, et al. CD99 acts as an oncosuppressor in osteosarcoma. Mol Biol Cell 2006;17:1910-1921.
44. Nam S, Williams A, Vultur A, et al. Dasatinib (BMS-354825) inhibits Stat5 signaling associated with apoptosis in chronic myelogenous leukemia cells. Mol Cancer Ther 2007;6:1400-1405.
45. Tokarski JS, Newitt JA, Chang CY, et al. The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Res 2006;66:5790-5797.
46. Chen Z, Lee FY, Bhalla KN, et al. Potent inhibition of platelet-derived growth factor-induced responses in vascular smooth muscle cells by BMS-354825 (dasatinib). Mol Pharmacol 2006;69:1527-1533.
47. Schittenhelm MM, Shiraga S, Schroeder A, et al. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res 2006;66:473-481.
48. Viereck V, Siggelkow H, Pannem R, et al. Alteration of the insulin-like growth factor axis during in vitro differentiation of the human osteosarcoma cell line HOS 58. J Cell Biochem 2007;102:28-40.
49. MacEwen EG, Pastor J, Kutzke J, et al. IGF-1 receptor contributes to the malignant phenotype in human and canine osteosarcoma. J Cell Biochem 2004;92:77-91.
50. Zhang H, Yee D. The therapeutic potential of agents targeting the type I insulin-like growth factor receptor. Expert Opin Investig Drugs 2004;13:1569-1577. (Pubitemid 39625142)
51. Beech D, Pollock RE, Tsan R, et al. Epidermal growth factor receptor and insulin-like growth factor-I receptor expression and function in human soft-tissue sarcoma cells. Int J Oncol 1998;12:329-336.
52. Roholl PJ, Skottner A, Prinsen I, et al. Expression of insulin-like growth factor 1 in sarcomas. Histopathology 1990;16:455-460.
53. Mitsiades CS, Mitsiades NS, McMullan CJ, et al. Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell 2004;5:221-230.
54. Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev 2004;18:1926-1945.
55. Bjornsti MA, Houghton PJ. The TOR pathway: a target for cancer therapy. Nat Rev Cancer 2004;4:335-348.
56. Castedo M, Ferri KF, Kroemer G. Mammalian target of rapamycin (mTOR): pro- and anti-apoptotic. Cell Death Differ 2002;9:99-100.
57. O'Reilly KE, Rojo F, She QB, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006;66:1500-1508.
58. Hay N. The Akt-mTOR tango and its relevance to cancer. Cancer Cell 2005;8:179-183.
59. Hosoi H, Dilling MB, Shikata T, et al. Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cells. Cancer Res 1999;59:886-894.
60. Abdeen A, Chou AJ, Healey JH, et al. Correlation between clinical outcome and growth factor pathway expression in osteogenic sarcoma. Cancer 2009;115:5243-5250.
61. Bajpai J, Sharma M, Sreenivas V, et al. VEGF expression as a prognostic marker in osteosarcoma. Pediatr Blood Cancer 2009;53:1035-1039.
62. Pignochino Y, Grignani G, Cavalloni G, et al. Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways. Mol Cancer 2009;8:118.
63. Schuetze SM. Chemotherapy in the management of osteosarcoma and Ewing's sarcoma. J Natl Compr Canc Netw 2007;5:449-455.
64. Whelan JS, McTiernan A, Kakouri E, et al. Carboplatin-based chemotherapy for refractory and recurrent Ewing's tumours. Pediatr Blood Cancer 2004;43:237-242.
65. Saylors RL III, Stine KC, Sullivan J, et al. Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study. J Clin Oncol 2001;19:3463-3469. (Pubitemid 32730082)
66. Hunold A, Weddeling N, Paulussen M, et al. Topotecan and cyclophosphamide in patients with refractory or relapsed Ewing tumors. Pediatr Blood Cancer 2006;47:795-800.
67. Wagner LM, McAllister N, Goldsby RE, et al. Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma. Pediatr Blood Cancer 2007;48:132-139.
68. Wagner LM, Crews KR, Iacono LC, et al. Phase I trial of temozolomide and protracted irinotecan in pediatric patients with refractory solid tumors. Clin Cancer Res 2004;10:840-848.
69. Mangham DC, Williams A, McMullan DJ, et al. Ewing's sarcoma of bone: the detection of specific transcripts in a large, consecutive series of formalin-fixed, decalcified, paraffin-embedded tissue samples using the reverse transcriptase-polymerase chain reaction. Histopathology 2006;48:363-376.
70. Turc-Carel C, Aurias A, Mugneret F, et al. Chromosomes in Ewing's sarcoma. I. An evaluation of 85 cases of remarkable consistency of t(11;22)(q24;q12). Cancer Genet Cytogenet 1988;32:229-238.
71. Sorensen PH, Lessnick SL, Lopez-Terrada D, et al. A second Ewing's sarcoma translocation, t(21;22), fuses the EWS gene to another ETS-family transcription factor, ERG. Nat Genet 1994;6:146-151. (Pubitemid 24188594)
72. Ohno T, Rao VN, Reddy ES. EWS/Fli-1 chimeric protein is a transcriptional activator. Cancer Res 1993;53:5859-5863. (Pubitemid 24006149)
73. Bailly RA, Bosselut R, Zucman J, et al. DNA-binding and transcriptional activation properties of the EWS-FLI-1 fusion protein resulting from the t(11;22) translocation in Ewing sarcoma. Mol Cell Biol 1994;14:3230-3241.
74. May WA, Gishizky ML, Lessnick SL, et al. Ewing sarcoma 11;22 translocation produces a chimeric transcription factor that requires the DNA-binding domain encoded by FLI1 for transformation. Proc Natl Acad Sci U S A 1993;90:5752-5756.
75. Toretsky JA, Kalebic T, Blakesley V, et al. The insulin-like growth factor-I receptor is required for EWS/FLI-1 transformation of fibroblasts. J Biol Chem 1997;272:30822-30827. (Pubitemid 27527522)
76. Martins AS, Mackintosh C, Martin DH, et al. Insulin-like growth factor I receptor pathway inhibition by ADW742, alone or in combination with imatinib, doxorubicin, or vincristine, is a novel therapeutic approach in Ewing tumor. Clin Cancer Res 2006;12:3532-3540.
77. Kolb EA, Gorlick R, Houghton PJ, et al. Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program. Pediatr Blood Cancer 2008;50:1190-1197.
78. Tolcher AW, Sarantopoulos J, Patnaik A, et al. Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1. J Clin Oncol 2009;27:5800-5807.
79. Scotlandi K, Manara MC, Nicoletti G, et al. Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors. Cancer Res 2005;65:3868-3876.
80. Kolb EA, Gorlick R. Development of IGF-IR inhibitors in pediatric sarcomas. Curr Oncol Rep 2009;11:307-313.
81. Patel S, Pappo A, Crowley J, et al. A SARC global collaborative phase II trial of R1507, a recombinant human monoclonal antibody to the insulin-like growth factor-1 receptor (IGF1R) in patients with recurrent or refractory sarcomas [abstract]. J Clin Oncol 2009;27(Suppl 1):Abstract 10503.
82. Burdach S, van Kaick B, Laws HJ, et al. Allogeneic and autologous stem-cell transplantation in advanced Ewing tumors. An update after long-term follow-up from two centers of the European Intergroup study EICESS. Stem-Cell Transplant Programs at Dusseldorf University Medical Center, Germany and St. Anna Kinderspital, Vienna, Austria. Ann Oncol 2000;11:1451-1462.
83. Burdach S, Meyer-Bahlburg A, Laws HJ, et al. High-dose therapy for patients with primary multifocal and early relapsed Ewing's tumors: results of two consecutive regimens assessing the role of total-body irradiation. J Clin Oncol 2003;21:3072-3078.
84. Meyers PA, Krailo MD, Ladanyi M, et al. High-dose melphalan, etoposide, total-body irradiation, and autologous stem-cell reconstitution as consolidation therapy for high-risk Ewing's sarcoma does not improve prognosis. J Clin Oncol 2001;19:2812-2820.
85. Gelderblom H, Hogendoorn PC, Dijkstra SD, et al. The clinical approach towards chondrosarcoma. Oncologist 2008;13:320-329.
86. Lagonigro MS, Tamborini E, Negri T, et al. PDGFRalpha, PDGFRbeta and KIT expression/activation in conventional chondrosarcoma. J Pathol 2006;208:615-623.
87. Sulzbacher I, Birner P, Trieb K, et al. Platelet-derived growth factor-alpha receptor expression supports the growth of conventional chondrosarcoma and is associated with adverse outcome. Am J Surg Pathol 2001;25:1520-1527.
88. Cleton-Jansen AM, van Beerendonk HM, Baelde HJ, et al. Estrogen signaling is active in cartilaginous tumors: implications for antiestrogen therapy as treatment option of metastasized or irresectable chondrosarcoma. Clin Cancer Res 2005;11:8028-8035.
89. Gelderblom H, Hohenberger P, Bovee JV, et al. Aromatase inhibition in patients with recurrent and/or metastatic chondrosarcoma [abstract]. J Clin Oncol 2008;26(Suppl 1):Abstract 10542.
90. Bovee JV, Cleton-Jansen AM, Taminiau AH, et al. Emerging pathways in the development of chondrosarcoma of bone and implications for targeted treatment. Lancet Oncol 2005;6:599-607.
91. Chow WA. Update on chondrosarcomas. Curr Opin Oncol 2007;19:371-376.
92. Miyaji T, Nakase T, Onuma E, et al. Monoclonal antibody to parathyroid hormone-related protein induces differentiation and apoptosis of chondrosarcoma cells. Cancer Lett 2003;199:147-155.
93. Tang GQ, Yan TQ, Guo W, et al. (-)-Epigallocatechin-3-gallate induces apoptosis and suppresses proliferation by inhibiting the human Indian Hedgehog pathway in human chondrosarcoma cells. J Cancer Res Clin Oncol 2010; in press.
94. Bovee JV, van den Broek LJ, Cleton-Jansen AM, et al. Up-regulation of PTHrP and Bcl-2 expression characterizes the progression of osteochondroma towards peripheral chondrosarcoma and is a late event in central chondrosarcoma. Lab Invest 2000;80:1925-1934.
95. Sakimura R, Tanaka K, Yamamoto S, et al. The effects of histone deacetylase inhibitors on the induction of differentiation in chondrosarcoma cells. Clin Cancer Res 2007;13:275-282.
96. Klenke FM, Abdollahi A, Berti E, et al. Tyrosine kinase inhibitor SU6668 represses chondrosarcoma growth via antiangiogenesis in vivo. BMC Cancer 2007;7:49.
97. Amichetti M, Cianchetti M, Amelio D, et al. Proton therapy in chordoma of the base of the skull: a systematic review. Neurosurg Rev 2009;32:403-416.